Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
Top Cited Papers
Open Access
- 17 March 2011
- Vol. 342 (mar17 1), d1309
- https://doi.org/10.1136/bmj.d1309
Abstract
Footnotes Contributors: YKL, CSK, and SS developed the concept and protocol for the review. CSK and YKL abstracted and analysed data. YKL, CSK, and SS wrote the manuscript. YKL had full access to all of the data in the study, takes responsibility for the integrity of the data and the accuracy of the data analysis, and is the guarantor. Funding: SS is supported by grant number 1KL2RR025006-03 from the NCRR, a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript was independent of any sources of funding. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Competing interests: All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that (1) they have no relationships with any company that might have an interest in the submitted work in the previous three years; (2) their spouses, partners, or children have no financial relationships that may be relevant to the submitted work; and (4) they have no non-financial interests that may be relevant to the submitted work. Data sharing: No additional data available.Keywords
This publication has 39 references indexed in Scilit:
- Long-term Risk of Cardiovascular Events With RosiglitazoneJAMA, 2007
- Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes MellitusJAMA, 2007
- Thiazolidinediones and Heart FailureDiabetes Care, 2007
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Comparison of evidence on harms of medical interventions in randomized and nonrandomized studiesCMAJ : Canadian Medical Association Journal, 2006
- Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes MellitusJAMA, 2005
- A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and DyslipidemiaDiabetes Care, 2005
- Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retentionProceedings of the National Academy of Sciences, 2005
- The Incidence of Congestive Heart Failure in Type 2 DiabetesDiabetes Care, 2004
- Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma.1998